within Pharmacolibrary.Drugs.ATC.L;

model L01AD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0033333333333333335,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.02,
    k12             = 125,
    k21             = 125
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Carmustine (BCNU) is a nitrosourea alkylating agent used as an antineoplastic (anticancer) drug, mainly for the treatment of brain tumors, multiple myeloma, and lymphomas. It is cytotoxic and works by cross-linking DNA and RNA, thereby inhibiting DNA replication and transcription. Carmustine is approved and still used clinically, particularly for brain tumors due to its ability to cross the blood-brain barrier.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients, typical dosing regimen; parameters for intravenous administration.</p><h4>References</h4><ol><li><p>Mali, A, &amp; Bhanwase, A (2025). In vivo pharmacokinetic study of carmustine in rats after giving single-dose of carmustine API solution, flexible liposomes, in situ nasal gel, optimized flexible liposomes embedded in situ nasal gel, and marketed formulation. <i>Annales pharmaceutiques francaises</i> 83(1) 112–123. DOI:<a href=&quot;https://doi.org/10.1016/j.pharma.2024.09.002&quot;>10.1016/j.pharma.2024.09.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39270836/&quot;>https://pubmed.ncbi.nlm.nih.gov/39270836</a></p></li><li><p>Tyler, JL, et al., &amp; Feindel, W (1986). Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 27(6) 775–780. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3486962/&quot;>https://pubmed.ncbi.nlm.nih.gov/3486962</a></p></li><li><p>Weingart, J, et al., &amp; Dolan, ME (2007). Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 25(4) 399–404. DOI:<a href=&quot;https://doi.org/10.1200/JCO.2006.06.6290&quot;>10.1200/JCO.2006.06.6290</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17264335/&quot;>https://pubmed.ncbi.nlm.nih.gov/17264335</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AD01;
